Life Sciences

  • June 22, 2026

    Can Unread Emails Trigger Arbitration? 9th Circ. Airs Doubts

    Medical supplies giant Thermo Fisher Scientific pressed a Ninth Circuit panel Monday to agree that the company's repeated emails about litigation waivers should send an ex-employee's proposed class action to arbitration, but the judges repeatedly questioned why no one simply asked if the worker saw the emails.

  • June 22, 2026

    Cassava Investors Ink $31M Drug Suit Deal Alongside Appeal

    Cassava Sciences investors have asked a Texas federal judge to preliminarily approve a $31 million settlement that ends their claims the pharmaceutical company inflated its stock prices with misleading information about its Alzheimer's drug research, a deal that could be upended if the court's class certification order is reversed on appeal.

  • June 22, 2026

    Zymergen Investors Get First OK For $125M Settlement

    Former executives, underwriters and large investors of now-defunct biotechnology company Zymergen received initial approval on Monday of a $125 million deal to end claims that they misled shareholders ahead of the company's initial public offering by approving misstatements about Zymergen's commercial product pipeline.

  • June 22, 2026

    FTC Requires Fix For Aurobindo's $250M Lannett Deal

    The Federal Trade Commission is allowing Aurobindo Pharma Ltd. to move ahead with its planned $250 million acquisition of Lannett Co. Inc., after the pharmaceutical company agreed to unload four generic drug products to prevent potential overlaps.

  • June 22, 2026

    No Trial For Splenda Maker, Scientist In Defamation Suit

    Splenda maker TC Heartland LLC and the scientist whom it accused of defamation were sent packing from North Carolina federal court Monday, after a judge found neither had offered evidence to overcome the other's First Amendment right to talk about scientific research.

  • June 22, 2026

    Sorrento RICO Case Naming Jackson Walker Gets Axed

    A Texas bankruptcy judge blocked a lawsuit in California federal court alleging Jackson Walker LLP and executives at Sorrento Therapeutics and M3 Partners conspired to forum shop in Texas so the drug developer could seek Chapter 11 protection in an "ethically compromised" bankruptcy court, ruling the suit's claims are barred by Sorrento's bankruptcy plan.

  • June 22, 2026

    NORML Fights Exclusion From DEA Pot Rescheduling Hearing

    The National Organization for the Reform of Marijuana Laws, a leading cannabis consumer advocate, has asked the U.S. Drug Enforcement Administration to reconsider its move freezing out all pro-reform voices from upcoming hearings on a proposal to reschedule marijuana.

  • June 22, 2026

    Yale Health Escapes Trade Law Claim In Insemination Suit

    Yale New Haven Health Services Corp. has defeated Connecticut trade law, emotional distress and informed consent claims in a lawsuit accusing a doctor of fraudulently using his own sperm to inseminate a fertility patient, but the hospital network holding entity must face a fraud allegation, a state judge has ruled.

  • June 22, 2026

    3rd Circ. Backs Quest Over Claims Of Bad 401(k) Management

    The Third Circuit on Monday affirmed Quest Diagnostics Inc.'s victory over a proposed class action accusing the company of mismanaging its employee 401(k) plan, holding the company followed a prudent process in deciding to retain two challenged investment funds despite periods of underperformance.

  • June 22, 2026

    Holland & Knight Adds Jones Day Atty To Atlanta, DC Teams

    Holland & Knight LLP has bolstered its ranks in Atlanta and Washington, D.C., by adding an attorney from Jones Day with experience helping clients navigate investigations brought by enforcers including the U.S. Department of Justice and the U.S. Securities and Exchange Commission. 

  • June 22, 2026

    USTR Launches Probe Into German Pharma Costs

    The U.S. Trade Representative has opened an investigation into whether Germany has been underpaying for certain pharmaceutical products in a way that burdens U.S. consumers with added costs, which could lead to added tariffs.

  • June 22, 2026

    Gov't Says It Should Face Vax IP Claims, Not Moderna

    The U.S. Department of Justice has told the Federal Circuit that multibillion-dollar patent infringement litigation should be directed at the government, instead of Moderna, for the drugmaker's development and supply of COVID vaccines during the pandemic.

  • June 22, 2026

    Justices Seek Solicitor General's Views On Drug Pricing Law

    The U.S. Supreme Court on Monday asked the federal government to weigh in on whether it should hear the pharmaceutical industry's challenge to Oregon's drug pricing transparency law, which drugmakers say forces them to justify pricing decisions and risks exposing trade secrets.

  • June 22, 2026

    Paul Weiss, Kirkland Steer $10.9B AbbVie, Apogee Deal

    AbbVie said Monday it has agreed to buy Apogee Therapeutics, a company developing therapies for inflammatory and immunological diseases, at a total equity value of approximately $10.9 billion, with Paul Weiss Rifkind Wharton & Garrison LLP and Kirkland & Ellis LLP advising. 

  • June 18, 2026

    Eli Lilly Weight Drug TM Deal Too Secretive, Ind. Judge Says

    An Indiana federal judge on Thursday refused to sign off on a confidential settlement that would bar a telehealth company from selling knock-offs of Eli Lilly's weight-loss medications, saying the companies didn't provide enough information for him to consider the deal.

  • June 18, 2026

    Express Scripts Can't Ditch Meta Wiretap Suit Yet

    A California federal judge refused to dismiss a proposed class action alleging Express Scripts lets Meta secretly read consumers' communications, saying a consumer sufficiently claimed the online pharmacy allowed Meta's unauthorized collection of personal health information.

  • June 18, 2026

    Fertility Chain Beats Suit Alleging Bogus Embryo Test Claims

    A fertility clinic chain has defeated a proposed class action accusing it of deceptively marketing its preimplantation genetic testing, after a Colorado federal judge found none of the patients claimed their own tests were inaccurate or caused a miscarriage or failed pregnancy.

  • June 18, 2026

    Novo Nordisk Sued Over Data Hack Tied To Extortionist Group

    Novo Nordisk was hit with a proposed negligence class action in New Jersey federal court alleging the pharmaceutical giant failed to have adequate data security measures in place to protect sensitive personal health information of patients and employees from being exposed to a cybercriminal extortionist group.

  • June 18, 2026

    Once Dominated By Patent Claims, IP Suits Now More Diverse

    Intellectual property litigation has become more spread out among patents, trademarks and copyrights over the years, as artificial intelligence and e-commerce systems have been drivers of legal matters, according to a new report.

  • June 18, 2026

    Full Fed. Circ. Skips DePuy Bid To Redo Spine Patent Dispute

    The full Federal Circuit won't revisit a panel decision that gave new life to an inventor's suit accusing DePuy Synthes Cos. of infringing his spinal realignment method patents, letting stand the decision that faulted a lower court's handling of expert testimony in the case.

  • June 18, 2026

    RFK Jr. Urges 1st Circ. To Reinstate His Vaccine Advisers

    U.S. Health Secretary Robert F. Kennedy Jr. told the First Circuit a Boston federal judge's decision to freeze his vaccine committee appointments lacks a legal foundation and has left the government paralyzed when it comes to vaccine policy.

  • June 18, 2026

    DEA Picks Only Pot Foes To Join Rescheduling Hearings

    The U.S. Drug Enforcement Administration on Thursday announced its selection of interested parties to participate in upcoming administrative hearings on a proposal to reclassify marijuana to a less restrictive status, each of whom is understood to oppose marijuana rescheduling.

  • June 18, 2026

    Cannabis World Cheers Justices' Gun Rights Ruling

    Cannabis industry stakeholders on Thursday largely applauded the U.S. Supreme Court's unanimous decision finding that a ban on gun ownership for drug users is unconstitutional as applied to a person who regularly uses marijuana.

  • June 18, 2026

    Goodwin, Latham Lead Biotech Kardigan's $400M IPO

    Venture-backed Kardigan Inc., a biotechnology firm developing therapies for cardiovascular diseases, hit the public markets on Thursday after raising $400 million in its initial public offering.

  • June 18, 2026

    Gibson Dunn Hires Ropes & Gray Health Regulatory Atty In DC

    Gibson Dunn & Crutcher LLP has hired a former Ropes & Gray LLP partner who works on a myriad of health regulatory and drug pricing matters, advising pharmaceutical manufacturers, investors and other entities on those issues, the firm announced Thursday.

Expert Analysis

  • Navigating Privilege Law Patchwork In Dual-Purpose Comms

    Author Photo

    Three years after the U.S. Supreme Court declined to resolve a circuit split in In re: Grand Jury, federal courts remain split as to when attorney-client privilege applies to dual-purpose legal and business communications, and understanding the fragmented landscape is essential for managing risks, say attorneys at Covington.

  • How AI Drafting Should Transform Patent Filing Strategies

    Author Photo

    As agentic artificial intelligence reduces the time and expense required to draft and file patents, companies should shift focus away from rationing drafting hours and more toward governing optionality, says Ian Schick at Paximal.

  • 5 Advertising Law Trends That Will Shape 2026

    Author Photo

    The legal landscape for advertisers will grow only more complex this year, with ongoing trends including a federal regulatory retreat, more aggressive action by the states, a focus on child privacy and expanded scrutiny of "natural" claims, say attorneys at Reed Smith.

  • Cannabis Industry Faces An Inflection Point This Year

    Author Photo

    Cannabis industry developments last year — from the passage of a new wholesale tax in Michigan, to an executive order accelerating the federal rescheduling process — presage a more mature phase of legalization this year, with hardening expectations and enforcement to come, says Alex Leonowicz at Howard & Howard.

  • Series

    Fly-Fishing Makes Me A Better Lawyer

    Author Photo

    Much like skilled attorneys, the best anglers prize preparation, presentation and patience while respecting their adversaries — both human and trout, says Rob Braverman at Braverman Greenspun.

  • 4 Ways GCs Can Manage Growing Service Of Process Volume

    Author Photo

    As automation and arbitration increase the volume of legal filings, in-house counsel must build scalable service of process systems that strengthen corporate governance and manage risk in real time, says Paul Mathews at Corporation Service Co.

  • Series

    The Law Firm Merger Diaries: Forming Measurable Ties

    Author Photo

    Relationship-building should begin as early as possible in a law firm merger, as intentional pathways to bringing people together drive collaboration, positive client response, engagements and growth, says Amie Colby at Troutman.

  • AG Watch: Va. Insulin Price Probe Signals Rising Scrutiny

    Author Photo

    Virginia Attorney General Jason Miyares' recent investigation into insulin manufacturers and pharmacy benefit managers for allegedly colluding to artificially inflate insulin prices reflects a broader trend to leverage consumer protection authority in high-impact healthcare matters, and the upcoming leadership change is unlikely to diminish scrutiny in this area, says Chuck Slemp at Cozen O'Connor.

  • FDA's AI Deployment Brings New Potential And Risks

    Author Photo

    The U.S. Food and Drug Administration's recent announcement about making agentic artificial intelligence tools available to agency employees may portend accelerated regulatory timelines and lower costs for drug companies and consumers, but potential errors and biases will necessitate additional safeguards, says Angela Silva at Lewis Brisbois.

  • 3 Key Takeaways From Planned Rescheduling Of Cannabis

    Author Photo

    An executive order reviving cannabis rescheduling represents a monumental change for the industry and, while the substance will remain illegal at the federal level, introduces several benefits, including improving state-legal cannabis operators' tax treatment, lowering the industry's legal risk profile, and leaving state-regulated markets largely intact, say attorneys at Dentons.

  • 6 Issues That May Follow The 340B Rebate Pilot Challenge

    Author Photo

    Though the Health Resources and Services Administration withdrew a pending case to reconsider the controversial 340B rebate pilot program, a number of crucial considerations remain, including the likelihood of a rework and questions about what that rework might look like, say attorneys at Spencer Fane.

  • 5 E-Discovery Predictions For 2026 And Beyond

    Author Photo

    2026 will likely be shaped by issues ranging from artificial intelligence regulatory turbulence to potential evidence rule changes, and e-discovery professionals will need to understand how to effectively guide the responsible and defensible adoption of emerging tools, while also ensuring effective safeguards, say attorneys at Littler.

  • Streamlining Product Liability MDLs With AI And Rule 16.1

    Author Photo

    With newly effective Rule 16.1 of the Federal Rules of Civil Procedure providing enhanced guidance on multidistrict litigation and the sophistication of artificial intelligence continuing to advance, parties have the opportunity to better confront the significant data challenges presented by product liability MDLs, say attorneys at Hollingsworth.

  • Business Considerations Amid Hemp Product Policy Change

    Author Photo

    With the passage of a bill fundamentally narrowing the federal definition of "hemp," there are practical and business considerations that brands, manufacturers and other parties should heed over the next year, including operational strategies, evaluating contract and counterparty risk, and tax implications, say attorneys at Foley Hoag.

  • Series

    Judges On AI: How Courts Can Boost Access To Justice

    Author Photo

    Arizona Court of Appeals Judge Samuel A. Thumma writes that generative artificial intelligence tools offer a profound opportunity to enhance access to justice and engender public confidence in courts’ use of technology, and judges can seize this opportunity in five key ways.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.